ARCHIVES

Conversation with The Cancer Letter: McKinsey Charge: Create Plan To Expand MD Anderson’s Reach

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival

August 31, 2012

Zaltrap Price Cut In Half Effective Immediately

November 8, 2012

In Brief: ACS Appoints Directors For Government Relations And Grassroots Development

April 25, 1997

Broder Responds To AACR Proposal, Cites Congressional ‘Commitment’

December 6, 1991

Clinical Trials: Stories On Results Can Have Unintended Consequences

May 15, 1998